Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.

Abstract: A three-dimensional-object can be effectively detected. A pair of image capture devices capture a three-dimensional-object and calculate disparity component data of subdivided-image regions, respectively. On a basis of the disparity component data, gray scale values indicative of distances from the image capture device are calculated and a gray scale image in which each region has its corresponding gray scale value is generated. A model of the three-dimensional-object is defined and correlation values is calculated to show the degree of a similarity between the model and the image subdivided regions in the gray scale image. The model is a two-dimensional image with a shaping characteristic when the three-dimensional object is viewed from positions of the image capture devices while each subdivided region of the two-dimensional image has a gray scale value indicative of a distance from the image capture device at a portion corresponding to the three-dimensional object.

Abstract: An object of the present invention is to provide a novel compound that is an agonist of guanosine-3?,5?-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3?,5?-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3?,5?-cyclic monophosphate compound as an active ingredient.

Abstract: A nucleic acid adsorbent in which a polymer having a constitutional unit represented by the following formula (I) is immobilized on a water-insoluble carrier is used as a nucleic acid adsorbent capable of selectively and efficiently adsorbing nucleic acids from complex mixtures, such as cell extract, wherein R1 represents hydrogen, fluoride, or methyl; R2 and R3 each independently represent alkyl of 1 to 6 carbon atoms; A is —NH— or —O—; and B represents alkylene of 2 to 18 carbon atoms. Nucleic acids are recovered from cell extract by allowing them to be adsorbed to the nucleic acid adsorbent by mixing this nucleic acid adsorbent with cell extract, removing the nucleic acids from the cell extract by separating the adsorbent therefrom, and dissociating the nucleic acids from the nucleic acid adsorbent by treating the separated nucleic acid adsorbent with alkali.

Abstract: The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3.

Abstract: It is found that blood cytochrome c levels quantified for non-alcoholic steatohepatitis patients are higher than those for healthy persons, and that the quantified blood cytochrome c values correlated with fat deposition rates in hepatocytes. It is possible to test non-alcoholic steatohepatitis by quantifying cytochrome c in serum. A test method and a test kit for the test are provided.

Abstract: The present invention provides a magnesium alloy material excellent in high mechanical characteristics without using special manufacturing facilities or processes and a method for manufacturing the magnesium alloy material. The magnesium alloy material is an Mg—Zn—RE alloy containing Zn as an essential component, at least one of Gd, Tb, and Tm as RE, and the rest including Mg and unavoidable impurities and contains a needle-like precipitate or a board-like precipitate (lengthy precipitate: X-phase=?-phase, ??-phase, and ?1-phase).

Abstract: An object to be achieved by the present invention is to provide a therapeutic means for heart disease such as myocardial ischemia or myocardial infarction. The present invention provides a therapeutic agent for heart disease which comprises a myocardial progenitor cell expressing MAP kinase TNNI3K at a high level as an active ingredient.

Abstract: A movable-body navigation information display unit is provided. In the movable-body navigation information display unit, a driver can intuitively and accurately recognize a relation between navigation information and a real picture or a real landscape. In addition, it is possible to avoid a state that visibility of a caution-needed picture such as a pedestrian in the real picture and a real picture of a road construction site is inhibited by an image of the navigation information. An image data creating section (405) matches road shape data with a road shape model to estimate posture data. In addition, the image data creating section creates picture (image) data for accurately compositing and displaying the image of the navigation information in an appropriate position in a real picture (or in a real landscape) of a road ahead of a movable body, and displays the navigation information as a three-dimensional icon or the like. A picture display section (5) performs display based on the picture data.

Abstract: The present invention provides a magnesium alloy material, having superior mechanical properties without using special production equipment or processes, and a production process thereof. The magnesium alloy material of the present invention composed of an Mg—Zn-RE alloy comprises essential components in the form of 0.5 to 3 atomic percent of Zn and 1 to 5 atomic percent of RE, with the remainder comprising Mg and unavoidable impurities. The Mg—Zn-RE alloy has a lamellar phase formed from a long period stacking ordered structure and ?-Mg in the alloy structure thereof. The long period stacking ordered structure has at least one of a curved portion and a bent portion and has a divided portion in at least a portion thereof. Finely granulated ?-Mg having a mean particle diameter of 2 ?m or less is formed in the divided portion.

Abstract: A nucleic acid adsorbent in which a polymer having a constitutional unit represented by the following formula (I) is immobilized on a water-insoluble carrier is used as a nucleic acid adsorbent capable of selectively and efficiently adsorbing nucleic acids from complex mixtures, such as cell extract, wherein R1 represents hydrogen, fluoride, or methyl; R2 and R3 each independently represent alkyl of 1 to 6 carbon atoms; A is —NH— or —O—; and B represents alkylene of 2 to 18 carbon atoms. Nucleic acids are recovered from cell extract by allowing them to be adsorbed to the nucleic acid adsorbent by mixing this nucleic acid adsorbent with cell extract, removing the nucleic acids from the cell extract by separating the adsorbent therefrom, and dissociating the nucleic acids from the nucleic acid adsorbent by treating the separated nucleic acid adsorbent with alkali.